Table 4 Demographic information of patients with intracranial haemorrhage.
From: The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
Pentoxifylline (n = 16) | Control (n = 28) | P-value | |
|---|---|---|---|
Age group (years) | 0.7237 | ||
18–59, n (%) | 3 (18.75) | 7 (25.00) | |
60 and above, n (%) | 13 (81.25) | 21 (75.00) | |
Gender | 0.8195 | ||
Female, n (%) | 8 (50.00) | 13 (46.43) | |
Male, n (%) | 8 (50.00) | 15 (53.57) | |
Aspirin used | 0.7625 | ||
No, n (%) | 12 (75.00) | 17 (60.71) | |
Non-regular, n (%) | 3 (18.75) | 9 (32.14) | |
Regular, n (%) | 1 (6.25) | 2 (7.14) | |
Comorbidities | |||
DM, n (%) | 8 (50.00) | 14 (50.00) | 1.0000 |
HTN, n (%) | 13 (81.25) | 23 (82.14) | 1.0000 |
Hyperlipidaemia, n (%) | 7 (43.75) | 8 (28.57) | 0.3069 |
Ischaemic stroke, n (%) | 4 (25.00) | 9 (32.14) | 0.7385 |
CAD, n (%) | 4 (25.00) | 7 (25.00) | 1.0000 |
ESRD, n (%) | 0 (0.00) | 4 (14.29) | 0.2797 |
EPO, n (%) | – | – | |
DAPT/anticoagulant, n (%) | 4 (25.00) | 6 (21.43) | 1.0000 |
Pentoxifylline | |||
< 800 mg/day, n (%) | 8 (50.00) | – | |
≥ 800 mg/day, n (%) | 8 (50.00) | – | |
Mortality, n (%) | 5 (31.25) | 10 (35.71) | 0.7638 |
